Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TP73 antisense RNA 1 (TP73-AS1, sometimes called KIAA0495 or PDAM) is a long non-coding RNA transcribed antisense to the TP73 gene at human chromosome 1p36.32. It acts primarily as a microRNA sponge, efficiently binding and sequestering human-specific miR-941 and other microRNAs such as miR-200, thereby modulating post-transcriptional gene regulation involved in cell migration, proliferation, and tumorigenesis. High expression of TP73-AS1 has been linked to adverse clinical outcomes and increased tumor grade in cancers such as glioma. TP73-AS1 holds promise as a biomarker for diagnosis and prognosis, and though not a conventional drug target (such as a receptor or enzyme), it represents a novel regulatory RNA molecule of increasing therapeutic interest in the context of oncology.
Not directly drugged; mechanism is via acting as a sponge for specific microRNAs, thereby regulating the downstream expression of their targets (e.g., tumor suppressors or oncogenes)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TP73 antisense RNA 1 (TP73-AS1).